T. Rowe Price Associates
CAMP icon

T. Rowe Price Associates’s CAMP4 Therapeutics CAMP Stock Holding History

T. Rowe Price Associates’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
+26,327
New +$114K ﹤0.01% 3127

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's CAMP Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 26,327 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #3127 among its holdings.

61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • T. Rowe Price Associates held 26,327 shares of CAMP4 Therapeutics worth $116K as of Q2 2026.
  • CAMP4 Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3127 holding.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.